Company news: Pfizer lupus collaboration; pharmacists want pharmas' help with patient support

Share this article:
Pfizer's Centers for Therapeutic Innovation is partnering with Alliance for Lupus Research to fund novel translational research projects through academic medical centers. ALR and CTI hope to find new therapies for lupus through the work of joint project teams made up of Pfizer scientists and academic researchers. The collaboration “represents an evolution of the R&D ecosystem,” said Pfizer, “in which industry works in close partnership with academia, non-profit organizations and other stakeholders to advance research and benefit patients.” Lupus, a chronic autoimmune disease, affects as many as 1.5 million Americans, mostly women in their childbearing years.

Pharmacists want drug companies to provide them with online access to resources for patient support, a Manhattan Research survey found. The firm surveyed 752 US pharmacists and found that more than three-quarters want access to online patient education materials and 64% of retail pharmacists want patient assistance or vouchers from companies through their electronic health records systems. Around two-fifths of pharmacists report spending more time on care and support of patients, including directing them to pharma company websites and apps, than they did two years ago, with top conditions being diabetes, cardiovascular disorders, pain, respiratory distress and psychosis/depression, in that order.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.